TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
Brief Summary: The purpose of this study is to analyze and compare the immunogenicity of Bivalent and Tetravalent vaccines against Human Papillomavirus in HIV-infected adult persons.


Options:
A: Arm Label: 0,2,6 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,3,9 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,6,12 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,12,24 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Intervention Type: BIOLOGICAL; Name: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): 0,12,24 month vaccination schedule, 0,2,6 month vaccination schedule, 0,3,9 month vaccination schedule, 0,6,12 month vaccination schedule
B: Arm Label: HIV+/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: HIV+/Aluminium Hydroxide Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo Control | Arm Label: HIV-/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): HIV+/Cervarix Group, HIV-/Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): HIV+/Aluminium Hydroxide Group
C: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®
D: Arm Label: 3-dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2 doses by default; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Single-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Unvaccinated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®); Assigned to Arm(s): 2 doses by default, 2-dose, 3-dose, Single-dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
Brief Summary: The purpose of this study is to analyze and compare the immunogenicity of Bivalent and Tetravalent vaccines against Human Papillomavirus in HIV-infected adult persons.


Options:
A: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®
B: Intervention Type: BIOLOGICAL; Name: HPV 16/18 VLP AS04; Assigned to Arm(s): N/A
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: Gardasil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 1 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 2 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 3 | Intervention Type: BIOLOGICAL; Name: Comparator: Gardasil; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 1; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 2; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 3; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection
Brief Summary: The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women.


Options:
A: Arm Label: Tenofovir 1% vaginal gel; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: Universal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Universal placebo gel | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): Tenofovir 1% vaginal gel | Intervention Type: DRUG; Name: Universal placebo gel; Assigned to Arm(s): Universal placebo gel
B: Intervention Type: DRUG; Name: Cellulose Sulfate Vaginal Gel (Microbicide); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acidform Lubricant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: HEC gel | Intervention Type: DRUG; Name: Acidform Lubricant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: HEC gel; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Universal HEC placebo) | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo (Universal HEC placebo); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IndiaCLEN Multicentric Trial of Home Versus Hospital Oral Amoxicillin for Management of Severe Pneumonia in Children
Brief Summary: The purpose of this study is to determine the safety and efficacy of oral amoxicillin in treating WHO defined severe pneumonia(cough and fast breathing with lower chest indrawing) at home and at hospital using an open labelled multicentric prospective two-arm randomized clinical trial to determine the differences in failure of treatment with a 7 day course of oral amoxicillin administered for first 48 hours in the hospital in comparison to being sent home after enrolment, in children 3 to 59 months old who have severe pneumonia. The investigators developmental hypothesis were to test whether the community/home based oral amoxicillin is efficacious for treating severe pneumonia.


Options:
A: Arm Label: Amoxicillin 45mg/kg 12 hourly; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin | Arm Label: Benzyl Penicillin 50,000IU/kg 6 hourly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benzyl penicillin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin 45mg/kg 12 hourly | Intervention Type: DRUG; Name: Benzyl penicillin; Assigned to Arm(s): Benzyl Penicillin 50,000IU/kg 6 hourly
B: Arm Label: Severe Pneumonia - Hospital Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Severe Pneumonia - Home Management; Type: EXPERIMENTAL; Interventions: Other: Severe Pneumonia - Home Management | Intervention Type: OTHER; Name: Severe Pneumonia - Home Management; Assigned to Arm(s): Severe Pneumonia - Home Management
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
D: Arm Label: Colistin and Meropenem; Type: EXPERIMENTAL; Interventions: Drug: Colistin, Drug: Meropenem | Arm Label: Colistin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colistin | Intervention Type: DRUG; Name: Colistin; Assigned to Arm(s): Colistin, Colistin and Meropenem | Intervention Type: DRUG; Name: Meropenem; Assigned to Arm(s): Colistin and Meropenem

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, Non-inferiority Study to Compare the Efficacy and Safety of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients
Brief Summary: This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.


Options:
A: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin
B: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: simvastatin/ezetimibe (vytorin) group; Type: EXPERIMENTAL; Interventions: Drug: simvastatin/ezetimibe | Arm Label: atorvastatin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin 20mg | Intervention Type: DRUG; Name: simvastatin/ezetimibe; Assigned to Arm(s): simvastatin/ezetimibe (vytorin) group | Intervention Type: DRUG; Name: atorvastatin 20mg; Assigned to Arm(s): atorvastatin group
D: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, Non-inferiority Study to Compare the Efficacy and Safety of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients
Brief Summary: This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.


Options:
A: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin | Arm Label: Simvastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): Simvastatin 40 mg QD
B: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 40 mg QD
C: Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin 20 mg, Simvastatin 40 mg
D: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Sham-Controlled Trial of Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia
Brief Summary: Studies using repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory auditory hallucinations (AH) in schizophrenia have shown promise. The majority of studies have examined the effect of low frequency left-sided stimulation (LFL) (i.e., 1 Hz) to the temporal parietal cortex (TPC). Priming stimulation (6 Hz) prior to LFL stimulation (hereby simply referred to as priming) has been shown to enhance the neurophysiological effects of LFL rTMS alone and, as such, may lead to greater attenuation of AH. Therefore, this study evaluated the efficacy of priming rTMS and LFL rTMS, compared to sham, applied to the TPC in patients with schizophrenia experiencing refractory auditory hallucinations (AH).


Options:
A: Arm Label: Real TMS; Type: ACTIVE_COMPARATOR; Interventions: Device: DEEP TMS H1 coil | Arm Label: Sham & real TMS; Type: PLACEBO_COMPARATOR; Interventions: Device: Deep H1 coil TMS | Intervention Type: DEVICE; Name: DEEP TMS H1 coil; Assigned to Arm(s): Real TMS | Intervention Type: DEVICE; Name: Deep H1 coil TMS; Assigned to Arm(s): Sham & real TMS
B: Arm Label: Low frequency left (LFL) sided rTMS; Type: EXPERIMENTAL; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Arm Label: Priming stimulation; Type: EXPERIMENTAL; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Intervention Type: DEVICE; Name: repetitive Transcranial Magnetic Stimulation; Assigned to Arm(s): Low frequency left (LFL) sided rTMS, Priming stimulation, Sham Control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Repetitive transcranial magnetic stimulation | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Sham repetitive transcranial magnetic stimulation | Intervention Type: OTHER; Name: Repetitive transcranial magnetic stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Sham repetitive transcranial magnetic stimulation; Assigned to Arm(s): 2
D: Arm Label: active tDCS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: active tDCS | Arm Label: sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Procedure: sham tDCS | Intervention Type: PROCEDURE; Name: active tDCS; Assigned to Arm(s): active tDCS | Intervention Type: PROCEDURE; Name: sham tDCS; Assigned to Arm(s): sham tDCS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: UMEC/VI 125/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI 125/25 mcg | Arm Label: UMEC/VI 62.5/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI 62.5/25 mcg | Arm Label: UMEC 125 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC 125 mcg | Arm Label: UMEC 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC 62.5 mcg | Arm Label: VI 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: VI 25 mcg | Intervention Type: DRUG; Name: UMEC/VI 125/25 mcg; Assigned to Arm(s): UMEC/VI 125/25 mcg | Intervention Type: DRUG; Name: UMEC/VI 62.5/25 mcg; Assigned to Arm(s): UMEC/VI 62.5/25 mcg | Intervention Type: DRUG; Name: UMEC 125 mcg; Assigned to Arm(s): UMEC 125 mcg | Intervention Type: DRUG; Name: UMEC 62.5 mcg; Assigned to Arm(s): UMEC 62.5 mcg | Intervention Type: DRUG; Name: VI 25 mcg; Assigned to Arm(s): VI 25 mcg
C: Arm Label: Umeclidinium 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium | Arm Label: Glycopyrronium 44 mcg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): Glycopyrronium 44 mcg
D: Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Brief Summary: The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.


Options:
A: Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): N/A
B: Arm Label: 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RC-1291 HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: RC-1291 HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): RC-1291 HCl | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 100 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Brief Summary: The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.


Options:
A: Arm Label: 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 100 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RC-1291 HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: RC-1291 HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): RC-1291 HCl | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial
Brief Summary: Are novel vascular closure devices noninferior to manual compression regarding access site complications after coronary angiography?


Options:
A: Arm Label: Manuel compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Arm Label: MynxGrip closure device; Type: EXPERIMENTAL; Interventions: Device: MynxGrip | Intervention Type: DEVICE; Name: MynxGrip; Assigned to Arm(s): MynxGrip closure device | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manuel compression
B: Arm Label: FemoSeal®; Type: EXPERIMENTAL; Interventions: Device: FemoSeal® | Arm Label: ExoSeal®; Type: EXPERIMENTAL; Interventions: Device: ExoSeal® | Arm Label: Manual compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Intervention Type: DEVICE; Name: FemoSeal®; Assigned to Arm(s): FemoSeal® | Intervention Type: DEVICE; Name: ExoSeal®; Assigned to Arm(s): ExoSeal® | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manual compression
C: Arm Label: FemoSeal®; Type: EXPERIMENTAL; Interventions: Device: FemoSeal® | Arm Label: Manual compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Intervention Type: DEVICE; Name: FemoSeal®; Assigned to Arm(s): FemoSeal® | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manual compression
D: Arm Label: Standard EVAR (IntuiTrak); Type: ACTIVE_COMPARATOR; Interventions: Device: SEVAR (IntuiTrak) | Arm Label: PEVAR (ProGlide closure); Type: EXPERIMENTAL; Interventions: Device: PEVAR (ProGlide closure) | Arm Label: PEVAR (ProstarXL closure); Type: EXPERIMENTAL; Interventions: Device: PEVAR (Prostar XL closure) | Intervention Type: DEVICE; Name: PEVAR (ProGlide closure); Assigned to Arm(s): PEVAR (ProGlide closure) | Intervention Type: DEVICE; Name: SEVAR (IntuiTrak); Assigned to Arm(s): Standard EVAR (IntuiTrak) | Intervention Type: DEVICE; Name: PEVAR (Prostar XL closure); Assigned to Arm(s): PEVAR (ProstarXL closure)

Answer: B